marked.bio

Company

DualityBio

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

DB-1303 1DB-1311 1pumitamig 1DB-1305 1

Trials

2 of 2 trials shown

  1. A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

    Active, not recruiting Phase 3 DualityBio Started 2024Primary completion 2026-08 NCT06018337

    DB-1303capecitabinepaclitaxelnab-paclitaxel

    Has HER2-low expression (IHC 1+ or IHC 2+/ISH-) as determined by the central laboratory result.

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Metastatic Breast Cancer

  2. DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

    Recruiting Phase 2 DualityBio Started 2025Primary completion 2030-06 NCT06953089

    DB-1311pumitamigDB-1305

    Not harboring an EGFR-sensitizing mutation or ALK gene rearrangements or other onco-driver gene mutations

    ALK fusionHER2-low / ultralow (IHC 1+ or 2+/ISH-)Solid Tumors